Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | C5 | P01031 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carprofen SCHEMBL29377449 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL30910956 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL29743273 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL29930903 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL5055325 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL30910975 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL3910 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL3909 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL30910972 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL9814869 | 0.99 | PTGS2 (0.97) | PTGS2MEN1ABCC4C5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192594-B2 | Ophthalmic solution for protecting internal structures of the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique | Sanseverino, Renato (IT) | 2015-11-24 | — | — | US | disclosed |
| EP-2459186-B1 | OPHTHALMIC SOLUTION FOR PROTECTING INTERNAL STRUCTURES OF THE EYEBALL AGAINST UV-A RAYS OR FOR THE TREATMENT OF KERATOCONUS WITH A TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE | TROISI SALVATORE (IT) | 2013-10-09 | — | — | EP | disclosed |
| US-20120121567-A1 | OPHTHALMIC SOLUTION FOR PROTECTING INTERNAL STRUCTURES OF THE EYEBALL AGAINST UV-A RAYS OR FOR THE TREATMENT OF KERATOCONUS WITH A TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE | TROISI, SALVATORE (IT) | 2012-05-17 | — | — | US | disclosed |
| US-20080269310-A1 | Synergistic Combinations | FOSTER ADRIAN PAUL | 2008-10-30 | — | — | US | disclosed |
| EP-1940380-A2 | SYNERGISTIC COMBINATIONS OF NON-STEROIDAL ANTIINFLAMMATORY DRUGS WITH ALPHA-2 DELTA-LIGANDS | Pfizer Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2006123247-A2 | SYNERGISTIC COMBINATIONS OF NON-STEROIDAL ANTIINFLAMMATORY DRUGS WITH ALPHA-DELTA-LIGANDS | PFIZER LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-20030212123-A1 | COX-2 selective carprofen for treating pain and inflammation in dogs | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| EP-0988034-A1 | COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS | PFIZER INC. (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998050033-A1 | COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS | PFIZER INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212123-A1 | COX-2 selective carprofen for treating pain and inflammation in dogs | PTGES2, PTGER2, PTGS2 | PTGS2 3/4885MEN1 4733/4885ABCC4 2978/4885 |
| US-20120121567-A1 | OPHTHALMIC SOLUTION FOR PROTECTING INTERNAL STRUCTURES OF THE EYEBALL AGAINST UV-A RAYS OR FOR THE TREATMENT OF KERATOCONUS WITH A TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE | MMP2, MMP9, MMP26 | PTGS2 270/4885MEN1 2728/4885ABCC4 3912/4885 |
| US-20080269310-A1 | Synergistic Combinations | GABRB2, GABRB3, GABRB1 | PTGS2 45/4885MEN1 4765/4885ABCC4 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.